JP2024537864A5 - - Google Patents
Info
- Publication number
- JP2024537864A5 JP2024537864A5 JP2024520855A JP2024520855A JP2024537864A5 JP 2024537864 A5 JP2024537864 A5 JP 2024537864A5 JP 2024520855 A JP2024520855 A JP 2024520855A JP 2024520855 A JP2024520855 A JP 2024520855A JP 2024537864 A5 JP2024537864 A5 JP 2024537864A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- seq
- specifically
- weeks
- risdiplam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21201211.6 | 2021-10-06 | ||
| EP21201211 | 2021-10-06 | ||
| PCT/EP2022/077494 WO2023057404A1 (en) | 2021-10-06 | 2022-10-04 | Novel combined administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537864A JP2024537864A (ja) | 2024-10-16 |
| JP2024537864A5 true JP2024537864A5 (https=) | 2025-11-11 |
Family
ID=78085538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520855A Pending JP2024537864A (ja) | 2021-10-06 | 2022-10-04 | 新規併用投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240358704A1 (https=) |
| EP (1) | EP4426306A1 (https=) |
| JP (1) | JP2024537864A (https=) |
| CN (1) | CN118055767A (https=) |
| WO (1) | WO2023057404A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4601651A1 (en) | 2022-10-14 | 2025-08-20 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
| US20250144031A1 (en) * | 2023-10-27 | 2025-05-08 | Hoffmann-La Roche Inc. | Composition for treating spinal muscular atrophy |
| CN118045206B (zh) * | 2024-04-12 | 2024-07-05 | 四川至善唯新生物科技有限公司 | 一种治疗脊髓型肌肉萎缩的药物组合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI3143025T1 (sl) | 2014-05-15 | 2020-01-31 | F. Hoffmann-La Roche Ag | Spojine za zdravljenje spinalne mišične atrofije |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| AR107078A1 (es) | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| CN115814077A (zh) * | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| NZ789269A (en) * | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| IL319888A (en) | 2018-10-19 | 2025-05-01 | Hoffmann La Roche | Forms of pyrido[2,1-A]pyrimidin-4-one derivatives, their formulations and process for their preparation |
-
2022
- 2022-10-04 WO PCT/EP2022/077494 patent/WO2023057404A1/en not_active Ceased
- 2022-10-04 CN CN202280067699.6A patent/CN118055767A/zh active Pending
- 2022-10-04 JP JP2024520855A patent/JP2024537864A/ja active Pending
- 2022-10-04 EP EP22802517.7A patent/EP4426306A1/en active Pending
-
2024
- 2024-04-05 US US18/627,727 patent/US20240358704A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537864A5 (https=) | ||
| JP2020518599A5 (https=) | ||
| JP2023515271A5 (https=) | ||
| JP2019534003A5 (https=) | ||
| CN103338772A (zh) | 用于预防或治疗青光眼的药物疗法 | |
| JP2022536469A5 (https=) | ||
| EP3982967A1 (en) | Methods for treating pulmonary arterial hypertension | |
| JP2022512704A5 (https=) | ||
| JP2024540226A5 (https=) | ||
| JP2024518536A5 (https=) | ||
| JP2021511043A5 (https=) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2021523138A5 (https=) | ||
| JP2023511956A5 (https=) | ||
| EP4076511A1 (en) | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies | |
| JP2022514561A5 (https=) | ||
| JP2021529766A5 (https=) | ||
| US20230227555A1 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| JP2023514567A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| CN100496500C (zh) | 含布那唑嗪和前列腺素的青光眼治疗剂 | |
| JP2022536669A5 (https=) | ||
| JP2025510725A5 (https=) | ||
| WO2024051670A1 (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |